Global Gadobutrol (CAS 138071-82-6) Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Gadobutrol (CAS 138071-82-6) Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Gadobitol is a gadolinium (ga) based, hydrophilic, electrically neutral compound with large rings. Gadobinol is commonly used as a diagnostic agent, and its solution (gadobinol injection) is often used as a Contrast agent for contrast-enhanced Magnetic Resonance Imaging (CE-MRI).

Market Overview:

The latest research study on the global Gadobutrol (CAS 138071-82-6) market finds that the global Gadobutrol (CAS 138071-82-6) market reached a value of USD 640.54 million in 2023. It’s expected that the market will achieve USD 1876.46 million by 2029, exhibiting a CAGR of 19.62% during the forecast period.

Gadobutrol is a macrocyclic, nonionic, extracellular, multipurpose, highly relaxed GBCA and is a major contrast enhancer for MRI. Gadobutrol has higher relaxation compared to gadoteric acid and gadoteridol, two macrocyclic GBCA. According to the article on the Clinical Efficacy of gadobutrol (from Investigative Radiology), gadobutrol was first approved for central nervous system imaging in Switzerland in 1998. Subsequently, MRA, liver and kidney imaging, and MRA for children over 2 years of age were approved. In 2012, it was approved as a general indication and in 2015, it was approved for children under 2 years old. Gadobutrol has been used more than 100 million times worldwide over the past 25 years, with a total of 7,856 patients enrolled in Phase II-IV clinical development studies and sold in 103 countries worldwide.

Gadobutrol is a new reagent, the prospective research on it will expand the application of the product and greatly promote the development of the industry. At present, Gadobutrol's research success in the brain, heart, thymus, prostate, bone and other aspects has promoted the development of its industry. According to a recent study, a 25% reduction in gadobutrol compared to a standard dose of gadoterate has effects on subjective CNS lesion enhancement, lesion boundary delineation, and lesion internal morphology, showing a 26% to 39% increase in relaxation of gadobutrol compared to gadoterate. The efficacy gain of gadobutrol enhancement is no less than that of gadoterate enhancement. Some researchers believe that a higher relaxation could support a reduction in Gd dose. In addition, for brain lesions, especially in patients undergoing multiple contra-enhanced examinations, dose reduction should be considered. The results of this study were the basis for the approval of the reduced dose of gadobutrol in CNS imaging in adults in Europe in 2022, allowing for the use of 0.075 mmol/kg bw gadobutrol as the minimal investigated dose, thus providing dose flexibility for the radiologists. In addition, the reduction in dosage can support the sustainable use of resources and the reduction of waste, which is also an important consideration for the future development of the next generation of macrocyclic GBCA.

Several prospective studies have shown that the sensitivity of gadobutrol enhanced breast MRI (CE-BMRI) for lesion detection ranges from 80 to 89 percent, which is significantly better than mammography (68 to 73 percent). the European Society of Breast Imaging 2022 recommendations suggest supplemental CE-BMRI for all women with extremely dense breasts.

It is expected that gadobutrol will be used in more MRI fields in the future, and circular gadolinium-based contrast agents will gradually replace linear gadolinium-based contrast agents, which will occupy more market share.

Region Overview:

North America is projected to account for a considerable share of the Gadobutrol (CAS 138071-82-6) market and is expected to become the largest region by 2028.

Company Overview:

Bayer is one of the major players operating in the Gadobutrol (CAS 138071-82-6) market, holding a share of 96.87% in 2023.

Bayer HealthCare Pharmaceuticals Inc. manufactures products relating to health and pharmaceuticals. The Company provides solutions for women's healthcare, diagnostic imaging, general medicine, hematology/neurology and oncology.

Segmentation Overview:

As for product types, the Single Dose Vials (2 mL, 7.5 mL, 10mL, and 15 mL) segment held the largest market share in 2022.

Single Dose Vials (2 mL, 7.5 mL, 10mL, and 15 mL) Single-dose vials are liquid drug vials for injection or infusion, intended for use in a single case, procedure, injection for a single patient. Single dose or single use vials are labeled by the manufacturer and usually do not contain antibacterial preservatives. Single doses of Gadobutrol is typically 2 mL, 7.5 mL, 10mL, and 15 mL .

Single Dose Pre-filled Injections (7.5 mL, 10 mL, 15 mL) Single Dose Pre-filled Injections are single-use syringes on which the manufacturer has fixed the needle. Gadobutrol is generally available in 7.5mL, 10 mL, and 15 mL

Pharmacy Bulk Packages (30 mL and 65 mL) A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses.

Application Overview:

By application, the Hospital segment occupied the biggest share from 2018 to 2022.

Hospital A hospital is a health care institution that treats patients and is equipped with specialized health science and paramedical personnel and medical equipment. Patients can undergo Mir-enhanced scans in the hospital.

Retail A clinic is a medical institution that focuses primarily on outpatient care. Clinics can be privately run or publicly managed and funded.

Patients can receive Mir-enhanced scans at the clinic.

Diagnostic Imaging Center The Diagnostic Imaging Center provides various services such as tumor imaging diagnosis, interventional radiology, and nuclear medicine.

Key Companies in the global Gadobutrol (CAS 138071-82-6) market covered in Chapter 3:

Vivere Imaging
Beijing Beilu Pharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Bayer HealthCare Pharmaceuticals Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Gadobutrol (CAS 138071-82-6) market from 2019 to 2030 is primarily split into:

Single Dose Vials (2 mL, 7.5 mL, 10mL, and 15 mL)
Single Dose Pre-filled Injections (7.5 mL, 10 mL, 15 mL)
Pharmacy Bulk Packages (30 mL and 65 mL)

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Gadobutrol (CAS 138071-82-6) market from 2019 to 2030 covers:

Hospital
In-versus
out-patient
Retail
Diagnostic Imaging Center

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)